| 000 | 01865 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250514020211.0 | ||
| 264 | 0 | _c20020110 | |
| 008 | 200201s 0 0 eng d | ||
| 022 | _a0165-5728 | ||
| 024 | 7 |
_a10.1016/s0165-5728(01)00432-5 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHussien, Y | |
| 245 | 0 | 0 |
_aGlatiramer acetate and IFN-beta act on dendritic cells in multiple sclerosis. _h[electronic resource] |
| 260 |
_bJournal of neuroimmunology _cDec 2001 |
||
| 300 |
_a102-10 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAdjuvants, Immunologic _xadministration & dosage |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntigens, CD _xanalysis |
| 650 | 0 | 4 |
_aAntigens, CD1 _xanalysis |
| 650 | 0 | 4 | _aB7-2 Antigen |
| 650 | 0 | 4 |
_aCell Differentiation _xdrug effects |
| 650 | 0 | 4 |
_aDendritic Cells _xchemistry |
| 650 | 0 | 4 | _aDrug Synergism |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFlow Cytometry |
| 650 | 0 | 4 | _aGlatiramer Acetate |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunophenotyping |
| 650 | 0 | 4 |
_aInterferon-beta _xadministration & dosage |
| 650 | 0 | 4 |
_aInterleukin-10 _xanalysis |
| 650 | 0 | 4 |
_aInterleukin-12 _xanalysis |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMembrane Glycoproteins _xanalysis |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMultiple Sclerosis, Chronic Progressive _xdrug therapy |
| 650 | 0 | 4 |
_aMultiple Sclerosis, Relapsing-Remitting _xdrug therapy |
| 650 | 0 | 4 |
_aPeptides _xadministration & dosage |
| 650 | 0 | 4 |
_aReceptors, Interleukin-3 _xanalysis |
| 650 | 0 | 4 |
_aTh2 Cells _xcytology |
| 700 | 1 | _aSanna, A | |
| 700 | 1 | _aSöderström, M | |
| 700 | 1 | _aLink, H | |
| 700 | 1 | _aHuang, Y M | |
| 773 | 0 |
_tJournal of neuroimmunology _gvol. 121 _gno. 1-2 _gp. 102-10 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0165-5728(01)00432-5 _zAvailable from publisher's website |
| 999 |
_c11644740 _d11644740 |
||